---
figid: PMC9675387__CNR2-5-e1720-g003
figtitle: 'Oncology biosimilars: New developments and future directions'
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC9675387
filename: CNR2-5-e1720-g003.jpg
figlink: /pmc/articles/PMC9675387/figure/cnr21720-fig-0003/
number: F3
caption: Epogen/Procrit and its biosimilars' mechanism of action. Once bound to the
  erythropoietin receptor, the JAK–STAT signaling pathway is activated, leading to
  red blood cell survival, proliferation, and differentiation.
papertitle: 'Oncology biosimilars: New developments and future directions.'
reftext: Rinda Devi Bachu, et al. Cancer Rep (Hoboken). 2022 Nov;5(11):e1720.
year: '2022'
doi: 10.1002/cnr2.1720
journal_title: Cancer Reports
journal_nlm_ta: Cancer Rep (Hoboken)
publisher_name: John Wiley and Sons Inc.
keywords: bevacizumab | biosimilars | epoetins | filgrastim | new developments | oncology
  | pegfilgrastim | rituximab
automl_pathway: 0.9738361
figid_alias: PMC9675387__F3
figtype: Figure
redirect_from: /figures/PMC9675387__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9675387__CNR2-5-e1720-g003.html
  '@type': Dataset
  description: Epogen/Procrit and its biosimilars' mechanism of action. Once bound
    to the erythropoietin receptor, the JAK–STAT signaling pathway is activated, leading
    to red blood cell survival, proliferation, and differentiation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - STAT3
  - JAK2
  - EPOR
  - RN7SL263P
  - KRAS
  - HRAS
  - NRAS
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
---
